238 related articles for article (PubMed ID: 20309679)
1. The structure of dopamine induced alpha-synuclein oligomers.
Rekas A; Knott RB; Sokolova A; Barnham KJ; Perez KA; Masters CL; Drew SC; Cappai R; Curtain CC; Pham CL
Eur Biophys J; 2010 Sep; 39(10):1407-19. PubMed ID: 20309679
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
3. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
4. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R
J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483
[TBL] [Abstract][Full Text] [Related]
5. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway.
Cappai R; Leck SL; Tew DJ; Williamson NA; Smith DP; Galatis D; Sharples RA; Curtain CC; Ali FE; Cherny RA; Culvenor JG; Bottomley SP; Masters CL; Barnham KJ; Hill AF
FASEB J; 2005 Aug; 19(10):1377-9. PubMed ID: 15946991
[TBL] [Abstract][Full Text] [Related]
6. Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study.
Pham CL; Kirby N; Wood K; Ryan T; Roberts B; Sokolova A; Barnham KJ; Masters CL; Knott RB; Cappai R; Curtain CC; Rekas A
Proteins; 2014 Jan; 82(1):10-21. PubMed ID: 23733394
[TBL] [Abstract][Full Text] [Related]
7. The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation.
Leong SL; Hinds MG; Connor AR; Smith DP; Illes-Toth E; Pham CL; Barnham KJ; Cappai R
PLoS One; 2015; 10(2):e0116497. PubMed ID: 25679387
[TBL] [Abstract][Full Text] [Related]
8. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
9. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
[TBL] [Abstract][Full Text] [Related]
10. Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions.
Zhou W; Long C; Reaney SH; Di Monte DA; Fink AL; Uversky VN
Biochim Biophys Acta; 2010 Mar; 1802(3):322-30. PubMed ID: 20026206
[TBL] [Abstract][Full Text] [Related]
11. Dopamine-mediated oxidation of methionine 127 in α-synuclein causes cytotoxicity and oligomerization of α-synuclein.
Nakaso K; Tajima N; Ito S; Teraoka M; Yamashita A; Horikoshi Y; Kikuchi D; Mochida S; Nakashima K; Matsura T
PLoS One; 2013; 8(2):e55068. PubMed ID: 23457458
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of α-synuclein oligomers using formaldehyde.
Ruesink H; Reimer L; Gregersen E; Moeller A; Betzer C; Jensen PH
PLoS One; 2019; 14(10):e0216764. PubMed ID: 31603909
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
[TBL] [Abstract][Full Text] [Related]
14. Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers.
Lee HJ; Baek SM; Ho DH; Suk JE; Cho ED; Lee SJ
Exp Mol Med; 2011 Apr; 43(4):216-22. PubMed ID: 21415592
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.
Shaltiel-Karyo R; Davidi D; Frenkel-Pinter M; Ovadia M; Segal D; Gazit E
Biochim Biophys Acta; 2012 Oct; 1820(10):1628-35. PubMed ID: 22575665
[TBL] [Abstract][Full Text] [Related]
16. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
[TBL] [Abstract][Full Text] [Related]
17. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding.
Pham CL; Cappai R
Biosci Rep; 2013 Oct; 33(5):. PubMed ID: 24066973
[TBL] [Abstract][Full Text] [Related]
18. SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway.
Giehm L; Oliveira CL; Christiansen G; Pedersen JS; Otzen DE
J Mol Biol; 2010 Aug; 401(1):115-33. PubMed ID: 20540950
[TBL] [Abstract][Full Text] [Related]
19. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.
Qin Z; Hu D; Han S; Reaney SH; Di Monte DA; Fink AL
J Biol Chem; 2007 Feb; 282(8):5862-70. PubMed ID: 17189262
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the non-fibrillar α-synuclein oligomers.
Hong DP; Han S; Fink AL; Uversky VN
Protein Pept Lett; 2011 Mar; 18(3):230-40. PubMed ID: 20858207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
